166 related articles for article (PubMed ID: 10090790)
1. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs.
Nakazato A; Ohta K; Sekiguchi Y; Okuyama S; Chaki S; Kawashima Y; Hatayama K
J Med Chem; 1999 Mar; 42(6):1076-87. PubMed ID: 10090790
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-dipropyl-4-methoxy-3-(2-phenylethoxy)phenylethylamine to discover sigma(1) ligands.
Nakazato A; Kumagai T; Ohta K; Chaki S; Okuyama S; Tomisawa K
J Med Chem; 1999 Sep; 42(19):3965-70. PubMed ID: 10508444
[TBL] [Abstract][Full Text] [Related]
4. NE-100, a novel sigma receptor ligand: in vivo tests.
Okuyama S; Imagawa Y; Ogawa S; Araki H; Ajima A; Tanaka M; Muramatsu M; Nakazato A; Yamaguchi K; Yoshida M
Life Sci; 1993; 53(18):PL285-90. PubMed ID: 7901723
[TBL] [Abstract][Full Text] [Related]
5. (+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties.
Ronsisvalle G; Marrazzo A; Prezzavento O; Pasquinucci L; Vittorio F; Pittalà V; Pappalardo MS; Cacciaguerra S; Spampinato S
J Med Chem; 1998 May; 41(10):1574-80. PubMed ID: 9572883
[TBL] [Abstract][Full Text] [Related]
6. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
[TBL] [Abstract][Full Text] [Related]
7. Phenylalkyl 1,2-diamines as sigma-receptor ligands: the discovery of novel antidepressant agents.
Kim YG; Seo SY; Heo J; Park CE; Lee EH; Choi YM
Methods Find Exp Clin Pharmacol; 2006; 28(1):7-11. PubMed ID: 16541191
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
9. Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
Agai-Csongor E; Nógrádi K; Galambos J; Vágó I; Bielik A; Magdó I; Ignácz-Szendrei G; Keseru GM; Greiner I; Laszlovszky I; Schmidt E; Kiss B; Sághy K; Laszy J; Gyertyán I; Zájer-Balázs M; Gémesi L; Domány G
Bioorg Med Chem Lett; 2007 Oct; 17(19):5340-4. PubMed ID: 17720494
[TBL] [Abstract][Full Text] [Related]
10. Effects of a novel, selective, sigma1-ligand, MS-377, on phencyclidine-induced behaviour.
Takahashi S; Takagi K; Horikomi K
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jul; 364(1):81-6. PubMed ID: 11485043
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Costantino L; Gandolfi F; Sorbi C; Franchini S; Prezzavento O; Vittorio F; Ronsisvalle G; Leonardi A; Poggesi E; Brasili L
J Med Chem; 2005 Jan; 48(1):266-73. PubMed ID: 15634021
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel N,N'-disubstituted piperazines as sigma receptor ligands.
Zhang Y; Williams W; Torrence-Campbell C; Bowen WD; Rice KC
J Med Chem; 1998 Dec; 41(25):4950-7. PubMed ID: 9836612
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET sigma receptor ligand.
Ishiwata K; Noguchi J; Ishii S; Hatano K; Ito K; Nabeshima T; Senda M
Nucl Med Biol; 1998 Apr; 25(3):195-202. PubMed ID: 9620623
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
Wu X; Chen J; Ji M; Varady J; Levant B; Wang S
Bioorg Med Chem Lett; 2004 Dec; 14(23):5813-6. PubMed ID: 15501046
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of apomorphine to discover sigma ligands: 6H-dibenzo[b,d]pyran and carbazole analogues.
Nakazato A; Sekiguchi Y; Ohta K; Chaki S; Okuyama S
Bioorg Med Chem; 1999 Sep; 7(9):2027-35. PubMed ID: 10530952
[TBL] [Abstract][Full Text] [Related]
18. Inhibition by sigma receptor ligand, MS-377, of N-methyl- D-aspartate-induced currents in dopamine neurons of the rat ventral tegmental area.
Yamazaki Y; Ishioka M; Matsubayashi H; Amano T; Sasa M
Psychopharmacology (Berl); 2002 Apr; 161(1):64-9. PubMed ID: 11967632
[TBL] [Abstract][Full Text] [Related]
19. Receptor site topographies for phencyclidine-like and sigma drugs: predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses.
Manallack DT; Wong MG; Costa M; Andrews PR; Beart PM
Mol Pharmacol; 1988 Dec; 34(6):863-79. PubMed ID: 2849051
[TBL] [Abstract][Full Text] [Related]
20. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
